FDA Calendar for Achillion Pharmaceuticals, Inc. (ACHN)

| Register (free)
Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.


Drug Pipeline

Drug NameType Of DrugFDA StatusDrug Phase
This company currently does not have any drugs. If you would like to create one please click here.


Events

No future events listed at this time, please check back later.

Add New Event

In order to write a comment you must first login.

Login or Register (for free!)

Add Event

ACHN

$11.73
-0.645 -5.21%
2/3/2012 4:00:00 PM

Sponsors

Other Links